Nápravníková Jana, Várady Marián, Vadlejch Jaroslav
Department of Zoology and Fisheries, Czech University of Life Sciences Prague, Prague, Czechia.
Institute of Parasitology, Slovak Academy of Sciences, Košice, Slovakia.
Front Vet Sci. 2022 Feb 21;9:833204. doi: 10.3389/fvets.2022.833204. eCollection 2022.
The control of strongylid infections has become challenging globally for equine practitioners due to the development of anthelmintic resistance. Comprehensive information on anthelmintic resistance in the Czech Republic, however, is still lacking. This study monitored the current efficacy of fenbendazole, pyrantel embonate, ivermectin and moxidectin. Forty-eight of 71 operations met the criteria (≥6 horses with ≥200 eggs per gram), with 969 fecal egg count reduction tests performed. Anthelmintic resistance was evaluated on an operation level based on fecal egg count reduction (FECR) and the lower limit of the 95% credible interval (LLCI) using Bayesian hierarchical models. General anthelmintic efficacy across all operations was assessed by posterior FECRs and the occurrence of sub-zero efficacies. Ivermectin and moxidectin demonstrated excellent efficacy (FECR 99.8-100%; 99.4-100 LLCI) in 45 and 23 operations, respectively, pyrantel embonate demonstrated sufficient efficacy in 15 operations and resistance was suspected in seven operations (FECR 88.1-99.1%; 72.5-98.5 LLCI). Fenbendazole, however, was not effective in a single operation (FECR 19.1-77.8%; 8.1-50.1 LLCI) out of 18. Fenbendazole had the highest probability of sub-zero efficacy (29.1%), i.e., post-treatment fecal egg counts exceeded the pre-treatment counts. Our data indicate an increase in the development of anthelmintic resistance, resulting in total failure of fenbendazole and a reduced efficacy of pyrantel embonate. Introducing advanced approaches of parasite control in the Czech Republic to slow the spread of anthelmintic resistance is thus needed.
由于抗蠕虫药耐药性的出现,对于全球的马医来说,控制圆线虫感染已变得具有挑战性。然而,捷克共和国仍缺乏关于抗蠕虫药耐药性的全面信息。本研究监测了芬苯达唑、吡喹酮、伊维菌素和莫西菌素的当前疗效。71例手术中有48例符合标准(≥6匹马,每克粪便虫卵数≥200个),共进行了969次粪便虫卵计数减少试验。基于粪便虫卵计数减少率(FECR)和使用贝叶斯分层模型的95%可信区间下限(LLCI),在手术层面评估抗蠕虫药耐药性。通过后验FECR和出现低于零的疗效来评估所有手术的总体抗蠕虫药疗效。伊维菌素和莫西菌素分别在45例和23例手术中显示出优异的疗效(FECR 99.8 - 100%;99.4 - 100 LLCI),吡喹酮在15例手术中显示出足够的疗效,在7例手术中怀疑有耐药性(FECR 88.1 - 99.1%;72.5 - 98.5 LLCI)。然而,在18例手术中,芬苯达唑在单一手术中无效(FECR 19.1 - 77.8%;8.1 - 50.1 LLCI)。芬苯达唑出现低于零疗效的概率最高(29.1%),即治疗后的粪便虫卵计数超过了治疗前的计数。我们的数据表明抗蠕虫药耐药性的发展有所增加,导致芬苯达唑完全失效,吡喹酮的疗效降低。因此,需要在捷克共和国引入先进的寄生虫控制方法,以减缓抗蠕虫药耐药性的传播。